Hologic Inc Stock Price, News & Analysis

Hologic (HOLX) reported Q2 FY2025 financial results with revenue of $1,005.3 million, slightly exceeding guidance but decreasing (1.2%) year-over-year. The company posted a GAAP diluted EPS loss of ($0.08) compared to $0.72 in the prior year, primarily due to $220.9 million in non-cash impairment charges. Non-GAAP EPS remained flat at $1.03. Key segment performance: - Diagnostics revenue: $453.6M (+0.8%) - Breast Health revenue: $356.2M (-7.4%) - Surgical revenue: $162.5M (+4.2%) - Skeletal health: $33.0M (+21.8%) The company maintained its full-year revenue guidance of $4,050-$4,100 million but lowered both GAAP and non-GAAP EPS guidance due to tariffs and geopolitical conditions. During Q2, Hologic repurchased 3.0 million shares for $200 million and ended with $1.43 billion in cash and cash equivalents.

Hologic (NASDAQ: HOLX) is presenting groundbreaking research on its AI-powered mammography technology at the Society of Breast Imaging Annual Symposium in Colorado Springs. A key study conducted at Massachusetts General Hospital analyzed 5,000 digital breast tomosynthesis screening exams using Hologic's Genius AI® Detection 2.0 solution.

The research examined 100 cancer cases initially missed by radiologists but later confirmed malignant, along with 500 previously identified cancers. The company is also showcasing its new Genius AI Detection PRO solution, which features a color-coded system for cancer detection confidence and has demonstrated up to 24% reduction in radiologists' reading time.

Additional highlights include the Envision™ Mammography Platform and contrast-enhanced mammography technology. The symposium includes informational sessions on implementing contrast-enhanced mammography and integrating AI into mammography practices.

Hologic (NASDAQ: HOLX) has released its 2024 sustainability report, highlighting significant progress in women's health initiatives and environmental commitments. The company's technologies impacted over 193 million lives worldwide in 2024, with major achievements including FDA clearance for the Genius™ Digital Diagnostics System and launch of Genius AI® Detection 2.0 for cancer screening.

Key environmental milestones include a commitment to 50% emissions reduction by 2030 and net zero by 2050, with a 10% emission reduction already achieved across Scopes 1, 2, and 3 since 2020. The company has reduced water usage by 20% at key sites and diverted 65% of waste from landfills.

Notable social achievements include maintaining a zero gender net pay gap, 97th percentile employee engagement, and $1.8M in corporate grants. The company expanded partnerships with organizations like the Black Women's Health Imperative and launched the fourth Global Women's Health Index with Gallup, covering 97% of the global adult population.

Hologic (NASDAQ: HOLX) has announced the election of Wayde McMillan to its Board of Directors, effective April 4, 2025. McMillan will also serve on the company's Audit and Finance Committee.

McMillan brings significant healthcare financial expertise, currently serving as CFO of Solventum since 2024, following his role as CFO of 3M Company's Health Care Business Group. His previous positions include Executive VP, CFO and Treasurer at Insulet (2019-2023), and CFO of Medtronic's Minimally Invasive Therapies Group (2015-2019). He also held various leadership roles at Covidien from 2006 to 2015.

McMillan holds a BS in Business Administration from Merrimack College and an MBA from Bentley University's McCallum Graduate School of Business.

Hologic (NASDAQ: HOLX) has announced it will release its second quarter fiscal 2025 financial results on Thursday, May 1, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern Time on the same day.

Participants can join the call by dialing (888) 394-8218 in the US and Canada, or +1 (773) 305-6853 for international callers, using access code 6553890. A webcast replay will be available on the company's investor relations website for 30 days following the call.

Hologic (Nasdaq: HOLX) has announced it will present at the Raymond James & Associates' 46th Annual Institutional Investors Conference on Tuesday, March 4 at 11 a.m. Eastern Time.

Investors and interested parties can access the live webcast through a link on the investors section of Hologic's website at http://investors.hologic.com. The webcast recording will remain available for 30 days following the event.

This presentation offers an opportunity for investors to gain insights into Hologic's current operations, strategies, and potential future developments.

Hologic (HOLX) has received CE Mark approval for its Affirm® Contrast Biopsy Software, a technology that combines contrast-enhanced diagnostic capabilities with lesion targeting for biopsy procedures. The software, which received FDA clearance in October 2020, integrates with Hologic's Selenia® Dimensions® and 3Dimensions™ systems.

The technology enables clinicians to target and acquire tissue samples in lesions identified through contrast-enhanced mammography (CEM), particularly in cases where correlation may not be found using tomosynthesis or ultrasound. It offers an alternative to MRI-guided biopsy with reduced noise and shorter examination times, potentially improving patient experience while reducing costs.

This software is part of Hologic's comprehensive contrast mammography and biopsy portfolio, which includes the Affirm Upright Biopsy System and I-View® 2.0 Contrast-Enhanced Mammography Software.

Hologic (NASDAQ: HOLX) has received FDA 510(k) clearance for its Aptima SARS-CoV-2 assay, upgrading from its previous Emergency Use Authorization (EUA) status granted in May 2020. The test detects SARS-CoV-2 RNA from nasopharyngeal or nasal swab samples, offering a less invasive testing option through nasal swabs.

The assay utilizes Hologic's transcription-mediated amplification (TMA) chemistry and runs on the Panther system, capable of processing over 1,000 tests daily with initial results in under three hours. The company has also secured FDA clearances for several other respiratory tests, including the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay for various sample types.

Hologic (HOLX) reported Q1 fiscal 2025 financial results with revenue of $1,021.8 million, up 0.9% year-over-year. The company achieved GAAP EPS of $0.87 and Non-GAAP EPS of $1.03, reaching the high end of guidance.

Key performance metrics include: Diagnostics revenue increased 5.1% to $470.6 million, Breast Health revenue decreased 2.3% to $369.1 million, and Surgical revenue grew 2.5% to $166.3 million. The company maintained strong cash flow from operations at $189.3 million and repurchased 6.8 million shares for $517 million.

Due to currency headwinds and weakness in breast health capital sales, Hologic lowered its full-year revenue guidance to $4,050-$4,100 million but maintained its non-GAAP EPS guidance of $4.25-$4.35. The company completed the acquisition of Gynesonics for approximately $350 million on January 2, 2025.